Robin Guo

1.2k total citations
27 papers, 611 citations indexed

About

Robin Guo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robin Guo has authored 27 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Robin Guo's work include Lung Cancer Treatments and Mutations (10 papers), Chromatin Remodeling and Cancer (5 papers) and Peptidase Inhibition and Analysis (4 papers). Robin Guo is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Chromatin Remodeling and Cancer (5 papers) and Peptidase Inhibition and Analysis (4 papers). Robin Guo collaborates with scholars based in United States, Taiwan and Spain. Robin Guo's co-authors include Alexander Drilon, Natasha Rekhtman, Jason C. Chang, Maria E. Arcila, Jia Luo, Mark G. Kris, Lufen Chang, Yun Yen, Jamie Sheren and Theresa A. Boyle and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Robin Guo

25 papers receiving 605 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin Guo United States 12 306 282 234 126 109 27 611
Mitchell D. Nambu United States 3 271 0.9× 351 1.2× 286 1.2× 169 1.3× 76 0.7× 3 648
Martina Makrutzki Spain 8 285 0.9× 268 1.0× 500 2.1× 66 0.5× 105 1.0× 14 699
Marianna Silletta Italy 14 214 0.7× 157 0.6× 224 1.0× 171 1.4× 87 0.8× 42 613
Shuta Ohara Japan 11 405 1.3× 299 1.1× 321 1.4× 59 0.5× 108 1.0× 37 627
Xuelian Chen China 12 209 0.7× 218 0.8× 462 2.0× 45 0.4× 163 1.5× 36 779
Fangfang Lü China 3 217 0.7× 151 0.5× 238 1.0× 72 0.6× 85 0.8× 4 458
Fa-Chyi Lee United States 9 156 0.5× 124 0.4× 193 0.8× 85 0.7× 57 0.5× 24 385
Ruixuan Geng China 12 196 0.6× 234 0.8× 254 1.1× 30 0.2× 148 1.4× 29 556
Vincenzo Ricci Italy 11 123 0.4× 158 0.6× 313 1.3× 51 0.4× 97 0.9× 33 477

Countries citing papers authored by Robin Guo

Since Specialization
Citations

This map shows the geographic impact of Robin Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Guo more than expected).

Fields of papers citing papers by Robin Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Guo. The network helps show where Robin Guo may publish in the future.

Co-authorship network of co-authors of Robin Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Guo. A scholar is included among the top collaborators of Robin Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Guo. Robin Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johannet, Paul, M. Herman Chui, Jason Konner, et al.. (2025). Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate. Gynecologic Oncology. 195. 173–179.
2.
Park, Wungki, Jian Zhang, Farshid Dayyani, et al.. (2024). Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3002–3002. 5 indexed citations
3.
Yap, Timothy A., Afshin Dowlati, Ibiayi Dagogo‐Jack, et al.. (2024). 1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation. European Journal of Cancer. 211. 114530–114530.
4.
Guo, Robin, Afshin Dowlati, Ibiayi Dagogo‐Jack, et al.. (2024). 603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation. Annals of Oncology. 35. S483–S484. 7 indexed citations
5.
Gormally, Michael V., Matteo Repetto, Justin Jee, et al.. (2024). A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types.. Journal of Clinical Oncology. 42(16_suppl). 3073–3073. 1 indexed citations
6.
Swisher, Elizabeth M., Linda Duska, Erika Hamilton, et al.. (2023). Abstract CT160: Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cance. Cancer Research. 83(8_Supplement). CT160–CT160. 3 indexed citations
7.
Dagogo‐Jack, Ibiayi, Afshin Dowlati, Robin Guo, et al.. (2023). 713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation. Annals of Oncology. 34. S493–S494. 2 indexed citations
8.
Guo, Robin, et al.. (2022). Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision. Cancer Treatment Reviews. 110. 102444–102444. 14 indexed citations
9.
10.
Gutierrez, Martin, Robin Guo, Giuseppe Giaccone, et al.. (2021). Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers. Lung Cancer. 162. 23–28. 17 indexed citations
11.
Guo, Robin, Jia Luo, Jason C. Chang, et al.. (2020). MET-dependent solid tumours — molecular diagnosis and targeted therapy. Nature Reviews Clinical Oncology. 17(9). 569–587. 210 indexed citations
12.
Guo, Robin, Mark G. Kris, Marc Ladanyi, et al.. (2019). Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. Journal of Thoracic Oncology. 15(4). 655–660. 22 indexed citations
13.
Guo, Robin, et al.. (2019). MA12.10 Novel Germline Mutations in DNA-Damage Repair and DNA Replication Identified in Patients with Malignant Pleural Mesothelioma (MPM). Journal of Thoracic Oncology. 14(10). S299–S299. 1 indexed citations
14.
Zhou, Changyou, Yan D. Zhao, Xin Mu, et al.. (2019). MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies. Journal of Thoracic Oncology. 14(10). S292–S292. 21 indexed citations
15.
Guo, Robin, Isabel R. Preeshagul, Adam J. Schoenfeld, et al.. (2019). P1.14-50 A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma. Journal of Thoracic Oncology. 14(10). S574–S575. 3 indexed citations
16.
Guo, Robin, Lynne D. Berry, Dara L. Aisner, et al.. (2019). MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. Journal of Thoracic Oncology. 14(9). 1666–1671. 116 indexed citations
17.
Guo, Robin, Michael Offin, A. Rose Brannon, et al.. (2019). MET inhibitor resistance in patients with MET exon 14-altered lung cancers.. Journal of Clinical Oncology. 37(15_suppl). 9006–9006. 22 indexed citations
18.
Guo, Robin, Jason C. Chang, S. Michael Rothenberg, et al.. (2019). Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases. JCO Precision Oncology. 3(3). 1–6. 33 indexed citations
19.
Chang, Lufen, Robin Guo, Qin Huang, & Yun Yen. (2013). Chromosomal Instability Triggered by Rrm2b Loss Leads to IL-6 Secretion and Plasmacytic Neoplasms. Cell Reports. 3(5). 1389–1397. 23 indexed citations
20.
Guo, Robin, Lufen Chang, Zheng Liu, et al.. (2011). Canonical Nuclear Factor κB Pathway Links Tumorigenesis of Synchronous Mantle-Cell Lymphoma, Clear-Cell Renal-Cell Carcinoma, and GI Stromal Tumor. Journal of Clinical Oncology. 29(10). e257–e261. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mitchell D. Nambu Breakdown of academic impact, for papers by Martina Makrutzki Breakdown of academic impact, for papers by Marianna Silletta Breakdown of academic impact, for papers by Shuta Ohara Breakdown of academic impact, for papers by Xuelian Chen Breakdown of academic impact, for papers by Fangfang Lü Breakdown of academic impact, for papers by Fa-Chyi Lee Breakdown of academic impact, for papers by Ruixuan Geng Breakdown of academic impact, for papers by Vincenzo Ricci
Rankless by CCL
2026